Search results
Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts
Investor's Business Daily· 2 years agoAmgen stock popped Friday after the drugmaker sweetened its 2022 outlook following a third-quarter...
Amgen Tumbles After Scrapping A $900 Million Prostate Cancer Drug
Investor's Business Daily· 7 months agoAmgen handily beat Wall Street's earnings forecasts Tuesday, but Amgen stock tumbled after the...
Why Is Amgen (AMGN) Down 4.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 year agoIt has been about a month since the last earnings report for Amgen (AMGN). Shares have lost about...
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
Zacks via Yahoo Finance· 2 years agoWith the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only...
These Drugs Are the New First Line of Defense Against Migraine
Verywell Health via Yahoo News· 1 month agoIllustration by Julie Bang for Verywell Health Fact checked by Nick Blackmer Key Takeaways CGRP...
Amgen (AMGN) Valuation: A Comprehensive Analysis of Its Market Value
GuruFocus.com via Yahoo Finance· 7 months agoAs of October 10, 2023, Amgen Inc (NASDAQ:AMGN) experienced a day's loss of -1.02%, with a 3-month...
Amgen Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance· 1 day agoAmgen Inc (NASDAQ:AMGN) has recently announced a dividend of $2.25 per share, set to be payable on June 7, 2024, with the ex-dividend date on May 16,...
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 9 months agoAmgen AMGN reported second-quarter 2023 earnings of $5.00 per share, which beat the Zacks Consensus...
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
Zacks via Yahoo Finance· 1 year agoFor new and old investors, taking full advantage of the stock market and investing with confidence...
Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
Zacks via Yahoo Finance· 2 years agoAmgen AMGN reported second-quarter 2022 earnings of $4.65 per share, which beat the Zacks Consensus...
